Cargando…

Advances in sequencing technologies for amyotrophic lateral sclerosis research

Amyotrophic lateral sclerosis (ALS) is caused by upper and lower motor neuron loss and has a fairly rapid disease progression, leading to fatality in an average of 2-5 years after symptom onset. Numerous genes have been implicated in this disease; however, many cases remain unexplained. Several tech...

Descripción completa

Detalles Bibliográficos
Autores principales: Udine, Evan, Jain, Angita, van Blitterswijk, Marka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838075/
https://www.ncbi.nlm.nih.gov/pubmed/36635726
http://dx.doi.org/10.1186/s13024-022-00593-1
_version_ 1784869207363551232
author Udine, Evan
Jain, Angita
van Blitterswijk, Marka
author_facet Udine, Evan
Jain, Angita
van Blitterswijk, Marka
author_sort Udine, Evan
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is caused by upper and lower motor neuron loss and has a fairly rapid disease progression, leading to fatality in an average of 2-5 years after symptom onset. Numerous genes have been implicated in this disease; however, many cases remain unexplained. Several technologies are being used to identify regions of interest and investigate candidate genes. Initial approaches to detect ALS genes include, among others, linkage analysis, Sanger sequencing, and genome-wide association studies. More recently, next-generation sequencing methods, such as whole-exome and whole-genome sequencing, have been introduced. While those methods have been particularly useful in discovering new ALS-linked genes, methodological advances are becoming increasingly important, especially given the complex genetics of ALS. Novel sequencing technologies, like long-read sequencing, are beginning to be used to uncover the contribution of repeat expansions and other types of structural variation, which may help explain missing heritability in ALS. In this review, we discuss how popular and/or upcoming methods are being used to discover ALS genes, highlighting emerging long-read sequencing platforms and their role in aiding our understanding of this challenging disease.
format Online
Article
Text
id pubmed-9838075
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98380752023-01-14 Advances in sequencing technologies for amyotrophic lateral sclerosis research Udine, Evan Jain, Angita van Blitterswijk, Marka Mol Neurodegener Review Amyotrophic lateral sclerosis (ALS) is caused by upper and lower motor neuron loss and has a fairly rapid disease progression, leading to fatality in an average of 2-5 years after symptom onset. Numerous genes have been implicated in this disease; however, many cases remain unexplained. Several technologies are being used to identify regions of interest and investigate candidate genes. Initial approaches to detect ALS genes include, among others, linkage analysis, Sanger sequencing, and genome-wide association studies. More recently, next-generation sequencing methods, such as whole-exome and whole-genome sequencing, have been introduced. While those methods have been particularly useful in discovering new ALS-linked genes, methodological advances are becoming increasingly important, especially given the complex genetics of ALS. Novel sequencing technologies, like long-read sequencing, are beginning to be used to uncover the contribution of repeat expansions and other types of structural variation, which may help explain missing heritability in ALS. In this review, we discuss how popular and/or upcoming methods are being used to discover ALS genes, highlighting emerging long-read sequencing platforms and their role in aiding our understanding of this challenging disease. BioMed Central 2023-01-13 /pmc/articles/PMC9838075/ /pubmed/36635726 http://dx.doi.org/10.1186/s13024-022-00593-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Udine, Evan
Jain, Angita
van Blitterswijk, Marka
Advances in sequencing technologies for amyotrophic lateral sclerosis research
title Advances in sequencing technologies for amyotrophic lateral sclerosis research
title_full Advances in sequencing technologies for amyotrophic lateral sclerosis research
title_fullStr Advances in sequencing technologies for amyotrophic lateral sclerosis research
title_full_unstemmed Advances in sequencing technologies for amyotrophic lateral sclerosis research
title_short Advances in sequencing technologies for amyotrophic lateral sclerosis research
title_sort advances in sequencing technologies for amyotrophic lateral sclerosis research
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838075/
https://www.ncbi.nlm.nih.gov/pubmed/36635726
http://dx.doi.org/10.1186/s13024-022-00593-1
work_keys_str_mv AT udineevan advancesinsequencingtechnologiesforamyotrophiclateralsclerosisresearch
AT jainangita advancesinsequencingtechnologiesforamyotrophiclateralsclerosisresearch
AT vanblitterswijkmarka advancesinsequencingtechnologiesforamyotrophiclateralsclerosisresearch